Latest News and Press Releases

NEW HAVEN, Conn., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will...

NEW HAVEN, Conn., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske, D.O. to the position of Executive Vice...

NEW HAVEN, Conn., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Anthony S. Gibney to the position of Executive Vice President...

- Global phase 2 clinical programs for ACH-4471 continue to expand in PNH and C3G -- Completed dosing phase 1 clinical study of ACH-5228 and initiated phase 1 study of ACH-5548 -- June 30, 2018 cash...

- Additional clinical compounds expand factor D portfolio opportunities - NEW HAVEN, Conn., July 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a clinical-stage...

NEW HAVEN, Conn., June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present...

- Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G - - Poster presentation detailing in vitro data showing no significant reduction in...

NEW HAVEN, Conn., May 04, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present...

 - Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 -  - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN,...

NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a...